Diadenosine tetraphosphate reduces toxicity caused by high-dose methamphetamine administration.
Diadenosine tetraphosphate (AP(4)A), two adenosine moieties bridged by four phosphates, is an endogenous purinergic ligand found in brain. Previous studies have shown that AP(4)A reduced neurodegeneration caused by the dopaminergic neurotoxin 6-hydroxydopamine in rat striatum and substantia nigra. The purpose of this study was to determine whether AP(4)A is protective against methamphetamine (MA)-mediated toxicity. Primary neuronal cultures were prepared from rat embryonic (E14-E15) ventral mesencephalic tissue. Cultures treated with 2mM MA exhibited decreased tyrosine hydroxylase (TH) immunoreactivity and increased cleaved caspase-3 immunoreactivity and TUNEL labeling. All these changes were lessened by pretreatment with AP(4)A. The protective effect of AP(4)A was also found in vivo. Adult Sprague-Dawley rats were injected with AP(4)A (25 microg/20 microl) or vehicle intracerebroventricularly followed by 4 doses of MA (5 or 10 mg/kg), given subcutaneously every 2h. Administration of MA reduced locomotor activity 1 day after injection, which was significantly antagonized by the pretreatment with AP(4)A. Using immunohistochemical analysis, TH fiber density at the substantia nigra pars reticulata was found reduced while cleaved caspase-3 immunoreactivity in striatum was increased after MA treatment; these responses were also significantly antagonized by AP(4)A. Taken together, our data show that AP(4)A has protective effects against MA-mediated toxicity both in vitro and in vivo. The mechanism of action involves suppression of MA-induced apoptosis.
Harvey
Brandon K
BK
National Institute on Drug Abuse, Intramural Research Program, Baltimore, MD 21224, United States.
Chou
Jenny
J
Shen
Hui
H
Hoffer
Barry J
BJ
Wang
Yun
Y
D000818:Animals; D053148:Caspase 3 / Q000378:metabolism; D018929:Cell Culture Techniques; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D015226:Dinucleoside Phosphates / Q000008:administration & dosage / Q000494:pharmacology*; D004298:Dopamine / Q000378:metabolism; D004347:Drug Interactions; D005260:Female; D008297:Male; D008636:Mesencephalon / Q000166:cytology; D008694:Methamphetamine / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D009043:Motor Activity / Q000187:drug effects; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000494:pharmacology*; D011247:Pregnancy; D051381:Rats; D017207:Rats, Sprague-Dawley; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D015226:Dinucleoside Phosphates; D018696:Neuroprotective Agents; D008694:Methamphetamine; C020733:diadenosine tetraphosphate; D014446:Tyrosine 3-Monooxygenase; D053148:Caspase 3; D004298:Dopamine